Please assess the completion status of the following clinical trial:

Trial Title: Phase I & Biological Study of Etanercept & Weekly Docetaxel in Patients With Advanced Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Must have pathologically or cytologically confirmed advanced solid malignancy for which there is no standard treatment exists.~* Solid malignancy that has persisted or recurred following prior therapy or advanced solid malignancy for which docetaxel is considered an acceptable first line treatment option:~  * Non-Small Cell Lung~ * Breast~ * Head and Neck~ * Esophageal~ * Stomach~ * Ovarian carcinomas~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-2~* Life expectancy of at least 12 weeks.~* Must have adequate organ function~* Peripheral Neuropathy must be less than Grade 2

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).